Fig. 3From: Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trialFasting plasma glucose, FPG (mg/dL) changes from baseline to 12 weeks and 24 weeks in FDC of MSP vs. MS groupBack to article page